Results 151 to 159 of about 20,923 (159)

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension

Diabetes Care, 2015
Afshin Salsali
exaly  

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Diabetes Care, 2014
Hans J Woerle, Hans-Ulrich Häring, Thomas Meinicke   +2 more
exaly  

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

Diabetes Care, 2018
Claudia Schmoor, Christoph Wanner, John M. Lachin   +2 more
exaly  

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

Diabetes Care, 2013
Hans J Woerle, Hans-Ulrich Häring, Thomas Meinicke   +2 more
exaly  

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

Diabetes, Obesity and Metabolism, 2014
Christopher S. Kovacs, H J Woerle, U C Broedl   +2 more
exaly  

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

Clinical Pharmacology in Drug Development, 2013
Gerhard Nehmiz, Sabine Pinnetti, Sreeraj Macha   +2 more
exaly  

Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?

Diabetes Care, 2016
Kim A Connelly, Andrew T Yan, Subodh Verma   +2 more
exaly  

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure.

JACC Basic To Translational Science, 2017
Nirmal Parajuli, Subodh Verma, Jason R B Dyck   +2 more
exaly  

Empagliflozin

Reactions Weekly, 2018
openaire   +1 more source